PMID- 25169522
OWN - NLM
STAT- MEDLINE
DCOM- 20150608
LR  - 20190606
IS  - 2476-762X (Electronic)
IS  - 1513-7368 (Linking)
VI  - 15
IP  - 16
DP  - 2014
TI  - Prognostic value of CD44 variant exon 6 expression in non-small cell lung cancer: 
      a meta-analysis.
PG  - 6761-6
AB  - BACKGROUND: CD44v6 (CD44 variant exon 6) is the chief CD44 variant isoform 
      regulating tumor invasion, progression, and metastasis. The prognostic value of 
      CD44v6 expression in non small cell lung cancer (NSCLC) has been evaluated in 
      many studies, but the results have remained controversial. Thus, we performed a 
      meta- analysis of currently available studies to investigate the prognostic value 
      of CD44v6 expression in NSCLC patients and the relationship between the 
      expression of CD44v6 and clinicopathological features. MATERIALS AND METHODS: Two 
      independent reviewers searched the relevant literature in Pubmed, Medline and 
      Embase from 1946 to January 2014. Overall survival (OS) and various 
      clinicopathological features were collected from included studies. This 
      meta-analysis was accomplished using STATA 12.0 and Revman 5.2 software. Pooled 
      hazard ratios (HRs) with 95% confidence intervals (95%CIs) were calculated to 
      estimate the effects. RESULTS: A total of 921 NSCLC patients from ten studies met 
      the inclusion criteria. The results showed that CD44v6 high expression was a 
      prognostic factor for poor survival (HR=1.91, 95%CI=1.12-3.26, p<0.05). With 
      respect to clinicopathological features, CD44v6 high expression was related to 
      histopathologic type (squamous cell carcinoma versus adenocarcinoma: OR=2.72, 
      95%CI=1.38-5.38, p=0.004), and lymph node metastasis (OR=3.02, 95%CI=1.93-4.72, 
      p<0.00001). CONCLUSIONS: Our results suggested CD44v6 high expression as a poor 
      prognostic factor for NSCLC, and CD44v6 expression is associated with lymph node 
      metastasis and histopathologic type. Therefore, CD44v6 expression can be used as 
      a novel prognostic marker in NSCLC cases.
FAU - Zhao, Shuang
AU  - Zhao S
AD  - Department of Respiratory Medicine, State Key Laboratory of Biotherapy and Cancer 
      Center, West China Hospital, Sichuan University, Chengdu, China E-mail : 
      weimin003@163.com.
FAU - He, Jin-Lan
AU  - He JL
FAU - Qiu, Zhi-Xin
AU  - Qiu ZX
FAU - Chen, Nian-Yong
AU  - Chen NY
FAU - Luo, Zhuang
AU  - Luo Z
FAU - Chen, Bo-Jiang
AU  - Chen BJ
FAU - Li, Wei-Min
AU  - Li WM
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PL  - Thailand
TA  - Asian Pac J Cancer Prev
JT  - Asian Pacific journal of cancer prevention : APJCP
JID - 101130625
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CD44 protein, human)
RN  - 0 (Hyaluronan Receptors)
RN  - 0 (Protein Isoforms)
SB  - IM
MH  - Adenocarcinoma/genetics
MH  - Biomarkers, Tumor/*genetics
MH  - Carcinoma, Non-Small-Cell Lung/*genetics/mortality/pathology
MH  - Carcinoma, Squamous Cell/genetics
MH  - Disease Progression
MH  - Female
MH  - Humans
MH  - Hyaluronan Receptors/biosynthesis/*genetics
MH  - Lung Neoplasms/*genetics/mortality/pathology
MH  - Lymphatic Metastasis/genetics
MH  - Male
MH  - Neoplasm Invasiveness
MH  - Prognosis
MH  - Protein Isoforms/genetics
EDAT- 2014/08/30 06:00
MHDA- 2015/06/09 06:00
CRDT- 2014/08/30 06:00
PHST- 2014/08/30 06:00 [entrez]
PHST- 2014/08/30 06:00 [pubmed]
PHST- 2015/06/09 06:00 [medline]
AID - 10.7314/apjcp.2014.15.16.6761 [doi]
PST - ppublish
SO  - Asian Pac J Cancer Prev. 2014;15(16):6761-6. doi: 10.7314/apjcp.2014.15.16.6761.